**PURPOSE:** The ability to modulate signaling pathways at the site of injury represents a novel paradigm in wound healing with implications for regenerative medicine and tissue engineering. Transforming growth factor-beta (TGF-β) activating kinase 1 (TAK1) is a key regulator in the TGF-β and bone morphogenetic protein (BMP) signaling pathways with central roles in proliferation, differentiation, survival, and apoptosis of myriad tissues during development and in a range of pathologic processes. Here we examine the effect of TAK1 inhibition both *in vitro* and in the *in vivo* wound environment. We introduce a novel dual inducible Cre/loxP and Flp/FRT recombinase system to precisely control the expression of TAK1 during wound healing and identify a role for TAK1 as a molecular switch between mesenchymal cell proliferation and differentiation.

**METHODS:** We developed a novel dual recombinase system (Cre/loxP; Flp/FRT) allowing TAK1 to be specifically inactivated (Ad.Cre) and sequentially re-activated afterwards (Ad.Flp). We first evaluated the effect of this system *in vitro* mesenchymal cells harvested from sites of musculoskeletal injury. Osteogenic differentiation was assayed via alizarin red and alkaline phosphatase staining. SMAD protein signaling was analyzed directly via immunocytochemistry and western blot analysis. Proliferation was assayed directly via BrdU and cell counting. *In vivo, c*ritical sized-calvarial defects (4mm) were performed and mice received either: 1. Ad.LacZ (control) or 2. Ad.Cre (inactivation) or 3. Ten days Ad.Cre (inactivation) followed by Ad.FLP (reactivation) to modulate *Tak1* expression. Calvarial tissue was harvested to assay for gene expression and cellular proliferation and differentiation were quantified histologically.

**RESULTS:** *In vitro* analysis of mesenchymal cells carrying the Ad.Flp/Ad.Cre construct demonstrated a significant loss in osteogenic potential (p\<0.05) and pSMAD1/5 signaling in the absence of *Tak1*. Reactivation of *Tak1* was sufficient to restore pSMAD1/5 signaling and osteogenic differentiation. Tak1 knockout demonstrated an opposite effect on cell proliferation with immediate and significant (p\<0.05) increases in cell growth upon knockout and normalization of cell proliferation on gene reactivation. Loss of *Tak1* in the calvarial wound environment resulted in increased presence of mesenchymal cells and increased expression of proliferative genes including *Ccnd1*, *E2f1*, and *Ki67*, an effect reversed by Ad.Flp reactivation of *Tak1*. Consistent with our *in vitro* data, loss of *Tak1* in calvarial tissue led to diminished osteogenic differentiation genes including *Bmp2*, *Tgfβ1*, *Col1*, *Ocn*, and *Runx2*. Again this effect was reversed by Ad.Flp reactivation of *Tak1*.

**CONCLUSION:** We demonstrate that precise control of Tak1 can be used to modulate a switch between proliferation and osteogenic differentiation in mesenchymal cells. These findings are possible due to a novel dual-recombinase system with applications in other animal models studying TGF-B signaling and TAK1. Our *in vivo* data suggests that therapeutic modulation of Tak1 may provide a target to control the proliferation/differentiation switch required during tissue regeneration.
